We Give Shareholders a Voice

Argos Therapeutics, Inc. (ARGS) Information Request Form

Levi & Korsinsky, LLP announces it has filed a complaint in the USDC for the Middle District of North Carolina on behalf of shareholders of Argos Therapeutics, Inc. (NASDAQ: ARGS) who purchased shares between February 7, 2014 and February 21, 2017.

Argos’ product candidate AGS-003 (rocapuldencel-T) is being evaluated in a pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The complaint alleges that Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).

On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.

If you suffered a loss in Argos you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Request More Information

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving Argos Therapeutics, Inc.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other Argos Therapeutics, Inc. shareholders.


Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear